Vancouver-based AbCellera Biologics will receive up to $175.6 million from the federal Strategic Innovation Fund to fast-track antibody therapies against COVID-19. The funding will also go to build a first-of-its-kind antibody manufacturing facility over the next four years to help Canada respond to future pandemics. AbCellera has partnered with global biopharmaceutical company Eli Lilly to…
Organization: Canadian COVID Genomics Network
Genome Canada launches $40-million COVID-19 gene sequencing network
A new national network is working to identify the tiny genetic differences that may explain why some infected people fall victim to COVID-19 more severely than others.